您的位置: 首页 > 农业专利 > 详情页

ANTAGONISTES D'ALK1 ET LEURS UTILISATIONS DANS LE TRAITEMENT DU NEPHROCARCINOME
专利权人:
BETH ISRAEL DEACONESS MEDICAL CENTER;ACCELERON PHARMA INC.
发明人:
BHATT, RUPAL S.,KUMAR, RAVINDRA,MIER, JAMES W.,PEARSALL, ROBERT,SHERMAN, MATTHEW,SOLBAN, NICOLAS
申请号:
CA2863188
公开号:
CA2863188A1
申请日:
2013.02.01
申请国别(地区):
CA
年份:
2013
代理人:
摘要:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit tumor growth of renal cell carcinoma (RCC) in vivo. In additional aspects the disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of ALK1 dramatically increases the ability of a standard of care receptor tyrosine kinase inhibitor to inhibit RCC tumor growth in vivo.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充